|Bid||84.86 x 100|
|Ask||85.12 x 100|
|Day's Range||84.90 - 85.56|
|52 Week Range||66.93 - 86.90|
|PE Ratio (TTM)||31.01|
|Dividend & Yield||2.72 (3.17%)|
|1y Target Est||N/A|
The future is infectious. There will be blood, which means there will be blood-borne viruses. Which means Gilead Sciences should continue to strike it rich from its leading drug franchises for the treatment of HIV and hepatitis C.
Juno Therapeutics Inc (NASDAQ:JUNO) has a lot going for it off and on the price chart. That doesn’t mean you shouldn’t immunize JUNO stock against the always-real bearish threats. To do that, we’ll explore a fully-hedged, collar-based therapy program. Let me explain.
In 1H17, Novartis’s (NVS) Galvus generated revenues of around $596 million compared to $589 million in 1H16.